LETTER TO THE EDITOR
J. Cutan. Immunol. Allergy
Severe lichenified skin rash associated with apalutamide administration
- CW
Chisato Watanabe
- SH
Shujiro Hayashi
- ST
Shown Tokoro
- KI
Ken Igawa
Dokkyo Medical University, Mibu, Japan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Prostate cancer is the second most commonly diagnosed malignancy in men worldwide 1,2 . For patients with castration-resistant prostate cancer, androgen deprivation therapy combined with second-generation androgen receptor inhibitors, such as apalutamide, has demonstrated improved disease progression and survival rates. 2 A dosedependent rash is a common adverse event, 3 while lichenoid drug eruption (LDE) has been rarely reported. 4 We present the case of a 78-year-old male (body mass index: 30.6) with a history of hypertension managed with amlodipine for 3 yr. One prior year, he was diagnosed with prostate cancer (cT4N1M1) and subsequently started on oral apalutamide (240 mg/day).Apalutamide was the first hormone treatment for his life. One month after initiating apalutamide therapy, he developed a rash on his upper limbs, which was asymptomatic.Despite topical corticosteroid treatment at a local clinic, the rash progressed. Six months after initiating apalutamide (5 months after rash onset), he was referr
Summary
Keywords
adverse drug reaction, lichenified skin rash, apalutamide, drug eruption, prostate cancer
Received
21 May 2025
Accepted
09 July 2025
Copyright
© 2025 Watanabe, Hayashi, Tokoro and Igawa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Shujiro Hayashi, shayashi@dokkyomed.ac.jp
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.